Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Completed · Phase 1

Conditions studied: Peripheral Arterial Occlusive Disease

In brief

The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD), (Rutherford's Grade II, category 4 or Grade III, category 5 and 6). Secondary objectives are: * To determine the biological activity of NV1FGF on collateral artery development. * To evaluate the activity of NV1FGF on hemodynamic and clinical parameters.

Key facts

Study ID

NCT01157156

Run by

Sanofi

People needed

51

Starts

1999-06-01

Expected to finish

2001-09-01

Last updated by the study team

2010-07-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Severe PAOD defined as Rutherford's Grade II, category 4 or Grade III, category 5 and 6
• Pain at rest for at least 2 weeks duration and/or trophic lesions for at least the previous 14 days with no signs of healing (no reduction in ulcer size or depth)
• Objective evidence of peripheral vascular disease (resting Ankle Brachial Index < 0.4 and/or resting Toe Brachial Index < 0.3 and/or metatarsal Peripheral Vascular Resistance flat or barely pulsatile in the diseased limb on 2 consecutive examinations performed at least 2 weeks apart)
• Angiographic demonstration of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries
• Poor candidate for surgical intervention or revascularization procedures (no tibial artery incontinuity as defined from mid-leg distance from the foot and no autologous tissue available)

You may not qualify if…

• Previous or current history of malignant disease. Patients who had successful tumor resection more than 10 years prior to inclusion into the study and had no recurrence and patients who had curatively resected basal/squamous cancer of the skin were allowed for inclusion
• Abnormal chest X-ray with suspected malignant tumor presence
• Positive stool hemoccult (expect if due to hemorrhoids)
• Positive Prostate Specific Antigen for men with suspected malignant tumor presence
• Abnormal mammography for women with suspected malignant tumor presence
• Papanicolaou smear (for women) of Class IV or Class V characterization
• Proliferative retinopathy
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Study site — Minneapolis, Minnesota, United States
• Study site — Tempere, Finland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.